NCT01415414View on ClinicalTrials.gov

Observational Study of Ultravist in Patients Requiring CECT

CompletedOBSERVATIONAL
Enrollment

11,660

Participants

Timeline

Start Date

September 30, 2011

Primary Completion Date

July 31, 2012

Study Completion Date

November 30, 2013

Conditions
Diagnostic Imaging
Interventions
DRUG

Iopromide (Ultravist, BAY86-4877)

CT enhancement for abdominal or pelvic scan. Generally doses of up to 1.5 g iodine per kg body weight are well tolerated

Trial Locations (1)

Unknown

Many Locations

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY

NCT01415414 - Observational Study of Ultravist in Patients Requiring CECT | Biotech Hunter | Biotech Hunter